Page 127 - 《中国药房》2020年22期

[ 6 ] 国家卫生计生委合理用药专家委员会，中国药师协会.心 charge：primary results of the randomised TRANSITION
力衰竭合理用药指南：第 2 版[J/CD].中国医学前沿杂 study[J]. Eur J Heart Fail，2019，21（8）：998-1007.
志：电子版，2019，11（7）：1-78. [15] WANG Y，ZHOU R，LU C，et al. Effects of the angioten-
[ 7 ] YANCY CW，JANUZZI JL，ALLEN LA，et al. 2017 ACC sin-receptor neprilysin inhibitor on cardiac reverse remod-
expert consensus decision pathway for optimization of eling：meta-analysis[J]. J Am Heart Assoc，2019，8（13）：
heart failure treatment：answers to 10 pivotal issues about 1-20.
heart failure with reduced ejection fraction：a report of the [16] VALENTIM GONCALVES A，PEREIRA-DA-SILVA T，
American College of Cardiology task force on expert con- GALRINHO A，et al. Antiarrhythmic effect of sacubi-
sensus decision pathways[J]. J Am Coll Cardiol，2018，71 tril-valsartan：cause or consequence of clinical improve-
（2）：201-230. ment?[J]. J Clin Med，2019. DOI：10.3390/jcm8060869.
[ 8 ] 陈存芳，贾博，江珊，等.沙库巴曲缬沙坦治疗射血分数中 [17] MARTENS P，BELIËN H，DUPONT M，et al. Insights in-
间值心力衰竭患者的疗效及预后[J].中国新药与临床杂 to implementation of sacubitril/valsartan into clinical prac-
志，2020，39（2）：88-92. tice[J]. ESC Heart Fail，2018，5（3）：275-283.
[ 9 ] SOLOMON SD，ZILE M，PIESKE B，et al. The angioten- [18] CANNON JA，SHEN L，JHUND PS，et al. Dementia-relat-
sin receptor neprilysin inhibitor LCZ696 in heart failure ed adverse events in PARADIGM-HF and other trials in
with preserved ejection fraction：a phase 2 double-blind heart failure with reduced ejection fraction[J]. Eur J Heart
randomised controlled trial[J]. Lancet，2012，380（9851）： Fail，2017，19（1）：129-137.
1387-1395． [19] BEJAN-ANGOULVANT T，GENET T，VRIGNAUD L，
[10] VADUGANATHAN M，CLAGGETT BL，DESAI AS，et al. et al. Three case reports of involuntary muscular move-
Prior heart failure hospitalization，clinical outcomes，and ments as adverse reactions to sacubitril/valsartan[J]. Br J
response to sacubitril/valsartan compared with valsartan Clin Pharmacol，2018，84（5）：1072-1074.
in HFpEF[J]. J Am Coll Cardiol，2020，75（3）：245-254. [20] ALMUFLEH A，MIELNICZUK LM，ZINOVIEV R，et al.
[11] PACKER M，CLAGGETT B，LEFKOWITZ MP，et al. Ef- Profound vasoplegia during sacubitril/valsartan treatment
fect of neprilysin inhibition on renal function in patients after heart transplantation[J]. Can J Cardiol，2018，34（3）：
with type 2 diabetes and chronic heart failure who are re- e5-e7.
ceiving target doses of inhibitors of the renin-angiotensin [21] VON LUEDER TG，SANGARALINGHAM SJ，WANG
system：a secondary analysis of the PARADIGM-HF tri- BH，et al. Renin-angiotensin blockade combined with na-
al[J]. Lancet Diabetes Endo，2018，6（7）：547-554. triuretic peptide system augmentation：novel therapeutic
[12] DU AX，WESTERHOUT CM，MCALISTER FA，et al. Ti- concepts to combat heart failure[J]. Circ Heart Fail，2013，
tration and tolerability of sacubitril/valsartan for patients 6（3）：594-605.
with heart failure in clinical practice[J]. J Cardiovasc [22] BÖHM M，YOUNG R，JHUND PS，et al. Systolic blood
Pharmacol，2019，73（3）：1-18. pressure，cardiovascular outcomes and efficacy and safety
[13] MARTENS P，LAMBEETS S，LAU CW，et al. Impact of of sacubitril/valsartan（LCZ696）in patients with chronic
sacubitril/valsartan on heart failure admissions：insights heart failure and reduced ejection fraction：results from
from real-world patient prescriptions[J]. Acta Cardiol， PARADIGM-HF[J]. Eur Heart J，2017，38（15）：1132-
2019，74（2）：115-122． 1143.
[14] WACHTER R，SENNI M，BELOHLAVEK J，et al. Initia- （收稿日期：2020-07-27 修回日期：2020-10-16）
tion of sacubitril/valsartan in haemodynamically stabi- （编辑：陈 宏）
lized heart failure patients in hospital or early after dis-

《中国药房》杂志——中国科技论文统计源期刊，欢迎投稿、订阅

中国药房 2020年第31卷第22期 China Pharmacy 2020 Vol. 31 No. 22 ·2805 ·